Press Releases

 
Press Releases
  Date Title and Summary View
Jul 19, 2017
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) an...
Jul 19, 2017
HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Wednesday, Aug. 9, 2017, at 10 a.m. ET, to review the company's financial results for the second quarter ended June 30, 2017. Mylan will release its financial results on Aug. 9,...
Jul 13, 2017
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, July 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed biosimilar trastuzumab. Th...
Jun 10, 2017
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessio...
Jun 7, 2017
HERTFORDSHIRE, England and PITTSBURGH, June 7, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) a leading global pharmaceutical company, today announced that the Company will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017, in Rancho Palos Verdes, CA. The presentation is scheduled to begin at 3:2...
Jun 2, 2017
HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug, Teva's Azilect® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated Ne...
Jun 2, 2017
HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Reclast® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New ...
May 23, 2017
DUBLIN, HERTFORDSHIRE, England and PITTSBURGH, May 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional efficacy and safety data from the three-month, pivotal Phase 3 studies of revefenacin (TD-4208) at the American Tho...
May 17, 2017
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 17, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that data from several studies of revefenacin (TD-4208) will be presented at the American Thoracic Society (ATS) International Conference, whic...
May 16, 2017
HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York City. The presentation is scheduled to begin at 2:30 p.m. ET. Interested par...
Page:
1
... NextLast
= add release to Briefcase